1,4,5Department of Pharmacology, VYWS, Institute of Pharmaceutical Education and Research, Borgaon (Meghe), Wardha, Maharashtra, India.
2,3Research Scholar, Department of Pharmaceutical Sciences, Rashtrasant Tukadoji Maharaj Nagpur University, Nagpur, Maharashtra, India.
Breynia rhamnoides, a lesser-known yet pharmacologically potent medicinal plant from the family Phyllanthocin, has recently drawn increasing scientific attention due to its broad spectrum of biological activities and ethnomedicinal relevance. Widely distributed in parts of South and Southeast Asia, it has been traditionally employed in various indigenous healing systems to treat ailments such as fever, wounds, diabetes, liver disorders, and infections. These traditional applications suggest the presence of multiple bioactive compounds, which are now beginning to be investigated through modern pharmacological and phytochemical research. Phytochemical screenings of Breynia rhamnoides have revealed the presence of important secondary metabolites such as flavonoids, alkaloids, phenolics, tannins, saponins, and terpenoids. These constituents are believed to contribute significantly to the plant’s observed antioxidant, anti-inflammatory, antimicrobial, antidiabetic, hepatoprotective, analgesic, and wound healing activities. Early studies, primarily conducted in vitro and animal models, support its therapeutic potential across multiple disease pathways. Notably, antioxidant activity is attributed to high phenolic content, while antidiabetic effects may involve insulin-sensitizing mechanisms and enzyme inhibition. Despite these promising pharmacological profiles, comprehensive scientific documentation on Breynia rhamnoides remains sparse. Limited clinical studies, lack of standardized extract formulations, and insufficient mechanistic insights hinder its development into validated herbal therapeutics or modern pharmaceutical agents. This review consolidates current knowledge of its botany, traditional uses, phytoconstituents, and pharmacological effects, offering a foundation for future exploration. To harness the full potential of Breynia rhamnoides, further in-depth research is essential, including advanced phytochemical analysis, toxicological profiling, pharmacokinetic studies, and clinical trials. With such efforts, Breynia ryanoids may contribute meaningfully to the fields of ethnopharmacology, natural product-based drug discovery, and integrative medicine.
1.1 Lithiasis
Urolithiasis, derived from the Greek words ‘ouron’ (urine), ‘oros’ (flow), and ‘lithos’ (stone), is a complex urological disorder characterized by the formation of calculi in the kidneys, bladder, and urethra. A condition known as lithiasis occurs when minerals accumulate in the bladder, ureter, renal system, or urinary tract, resulting in the formation of stones or crystals. The formation of kidney stones results from an imbalance between promoters, such as uric acid, and inhibitors, such as magnesium.1
Numerous sources indicate that-
Calcium oxalate calculi commonly form when the solubility limit of a few calcium salts in urine is exceeded7. One of the primary pathogenic events in stone development is the supersaturation of urine with elements that could cause stones, such as struvite, calcium oxalate, uric acid, and cystine8. Ancient Sanskrit writings from India, dating back to 3000-2000 BC, include the Susruta Samhita, a surgical textbook on urinary stone removal, and Acharya Charaka's Charaka Samhita, which focuses on urologic diseases. Charaka emphasizes prevention over cure in Ayurvedic medicine, mentioning kidney stone formation, a condition that has persisted for generations and remains prominent today.9 Kidney stones are formed by mineral crystallization and form a rigid mass, varying in size and location. Common symptoms include high fever, vomiting, frequent urination, abdominal pain, and blood in the urine. In severe cases, blood may appear in the urine alongside pain. Infections can cause fever and chills. Less common symptoms include foul-smelling or cloudy urine, vague stomach pain, burning sensations, rib pain, blood in the urine, dizziness, and repeated urinary tract infections.10 Urolithiasis affects people of all ages, with males being more likely to develop it than females. Calcium oxalate stones are most prevalent in the age range of 50-60. Kidney stones are more common in young women, but men are more likely to develop them due to their higher muscle mass, leading to higher prevalence rates of kidney stones in men 11 Men are more likely to develop kidney stones due to the pro-stone-forming effects of testosterone and the anti-stone-forming effects of estrogen. Additionally, men may break down tissues faster, leading to more metabolic waste and an increased risk of kidney stones.12 Estrogen can help prevent calcium stones in the male urinary tract by keeping urine alkaline and raising citrate levels, as the male urinary tract is more complex than the female 13. Recent surveys show a significant increase in kidney stone disease among women between 1997 and 2002, possibly due to lifestyle factors like obesity. The male-to-female ratio has been shifted from 1.7:1 to 1.3:1, and vegetarians may have a lower risk of kidney stones compared to non-vegetarians. 14 Kidney stones, a prevalent urinary system issue, affect 19.1% of men and 9.4% of women, increasing from 3.2% in 1976-1980 to 8.8% in 2014, linked to obesity and diabetes.15
Calculi can cause serious medical issues like blockage, infection, hydronephrosis, and urinary tract bleeding if not diagnosed. Common surgical methods include lithotripsy and high-power laser disruption, but they can cause acute renal damage and decrease renal function if not addressed. Over 80% of urinary calculi are calcium oxalate or calcium phosphate stones, highlighting the global prevalence of lithiasis. Men are more likely to have nephrolithiasis (12%), and both sexes are more likely to develop it between the ages of 20 and 40, according to epidemiological studies.16
1.2 History of kidney stone
Urinary stones have a long history, dating back to the Ancient Egyptians. In 1901, E. Smith discovered a bladder stone in a mummy in Egypt. Treatments for stones were mentioned in Egyptian medical writings from 1500 BC17. The earliest literary quotations about stone disease were found in the Asutu medical texts between 3200 and 1200 BC. The first descriptions of "cutting for the stone" were found in Hindu and Greek writings. Sushruta, a surgeon from ancient India, wrote a book about over 300 surgical procedures, including perineal lithotomy, in his book Sushruta Samhita.18 Ancient India recommended a vegetarian diet, medicated milk, clarified butter, and alkalis for treating stone sufferers, with surgery used if unsuccessful, as detailed in Sushruta's works.19
Ancient Greeks' Early Observations and Documentation on Urinary Stone Disease
• Hippocrates (460-377 BC) described kidney diseases and bladder stone symptoms.
• Hippocrates' Oath of Medical Ethics for physicians emphasized avoiding stone cutting.
• Litotomy was practiced with perineal incision, and bladder wounds were lethal.20
Ammonius of Alexandria, 276 BC, was the first to suggest crushing a stone for removal. He stabilized the stone with a hook and used a blunt-ended instrument to split it. He coined the term "lithotomus" for cutting the stone, but his idea didn't gain popularity.21
The 20th century marked a paradigm shift in urolithiasis management. The introduction of extracorporeal shock wave lithotripsy (ESWL) in the 1980s revolutionized treatment by allowing non-invasive stone fragmentation.22 Innovations in ureteroscopy, percutaneous nephrolithotomy, and laser lithotripsy using Holmium: YAG and Thulium fiber lasers have significantly improved stone clearance rates and reduced complications.23 Contemporary research (2020–2025) focuses on precision medicine, improved laser technologies, and metabolic stone prevention. Thulium Fiber Laser (TFL) has emerged as a superior alternative to Holmium: YAG due to its smaller fiber size, lower retropulsion, and finer dusting capability, especially for hard stones.24 Additionally, miniaturized PCNL techniques such as Mini-PCNL, Ultra-mini, and Micro-PCNL are increasingly used to manage large renal stones in pediatric and adult populations. Mini PCNL and standard PCNL have similar effectiveness in stone-free rate management, regardless of factors like sex, body composition, location, and stone composition. Mini-PCNL is preferred by endocrinologists due to its high efficacy, low morbidity, and short hospital stay. Standard PCNL is the most morbid option, while RIRS is the safest option with acceptable SFR, low morbidity, and short hospital stay for large renal stones.25,26 There is also a growing emphasis on metabolic evaluation and dietary management to prevent recurrence. Genetic studies are beginning to identify mutations associated with stone formation, such as in Cystinuria, opening doors to targeted therapies. 27 The integration of AI and machine learning models is enhancing diagnostic accuracy, improving treatment decisions, and predicting stone composition.28
1.3 Human Excretory System
<a href="https://www.ijpsjournal.com/uploads/createUrl/createUrl-20250603121958-10.png" target="_blank">
<img alt="Human Excretory System.png" height="150" src="https://www.ijpsjournal.com/uploads/createUrl/createUrl-20250603121958-10.png" width="150">
</a>
Figure No.1: Human Excretory System
The human kidneys are mesodermal in origin, specifically metanephric, and are essential organs in the excretory system28. Typically, there are two kidneys located in the abdominal cavity, each situated on the posterior-dorsal aspect of the abdominal wall in the lumbar region. They are positioned on either side of the vertebral column, spanning from the Level of the T12 to the L2 vertebrae. The right kidney is generally slightly lower than the left, accommodating the liver's position.? Each kidney has a characteristic bean shape and a reddish-brown hue. In adults, the average kidney dimensions are approximately 10 cm in length, 5 cm in breadth, and 4 cm in thickness, with a typical weight of about 140 grams, constituting roughly 1% of total body weight. The kidneys are retroperitoneal, meaning they lie between the peritoneum and the dorsal body wall, being covered by the peritoneum only on the ventral side. They are also deeply embedded in adipose tissue, which provides cushioning and protection.29,30
1.4 Anatomy of the Kidney
The kidneys are two organs located on either side of the spinal column and behind the peritoneum. They remove excess salt, water, and metabolic waste from the blood while maintaining its pH balance. Positioned in the lumbar, umbilical, hypochondriac, and epigastric regions, they extend vertically from the middle of the third lumbar vertebra to the top margin of the twelfth thoracic vertebra. The left kidney is situated closer to the body's center than the right kidney, and both cross the transpyloric plane. The kidneys are approximately 11.0 cm in length, 6.0 cm in width, and 3.0 cm in thickness, resembling beans in shape. Male kidneys typically weigh around 150 g, while female kidneys weigh about 135 g. They are reddish-brown.31
<a href="https://www.ijpsjournal.com/uploads/createUrl/createUrl-20250603121958-9.jpg" target="_blank">
<img alt="Inner Structure of the Kidney.jpg" height="150" src="https://www.ijpsjournal.com/uploads/createUrl/createUrl-20250603121958-9.jpg" width="150">
</a>
Figure No.2: Inner Structure of the Kidney
The longitudinal section of the kidney consists of two distinct regions: the outer cortex, a dark red area, and the inner medulla, a pale red area.
1.5 Function of the kidney
The kidneys are important organs that perform several functions, including:
The classification of renal disease can be determined by analyzing five physiological factors.-
• Obstructive uropathy, also known as obstructive uropathy, affects any part of the urinary tract, including the kidneys and urethral meatus.
• It can cause pain, urinary tract infection, decline in renal function, sepsis, or even death.
• The severity of renal failure and urinary tract obstruction depends on the severity and duration of the obstruction.
• Urine stasis, an increase in the risk of urine infection, can occur when the urinary system is clogged.
• Comprehensive history and physical evaluation are essential for proper patient evaluation.
Increased Rate of Renal Calculi
• The incidence of renal calculi is increasing due to changes in diet, lifestyle, obesity, etc.
• In 2012, 10.6% of men and 7.1% of women reported with renal calculi.
• The incidence ratio of renal calculi related to obesity and age is 1.76 for women with a BMI of > 32 kg/m2 and 1.38 for men.
• The prevalence of renal calculi increases with increased intake of caffeinated and sugar-containing beverages.
Kidney stones are formed due to reduced urine output or increased excretion of substances like calcium, oxalate, urate, cystine, xanthine, and phosphate. They grow in the kidney's pelvis and can range in size from microscopic to staghorn stones. The pain is sudden, intense, and radiates from the back, flank, and groin. Risk factors include decreased fluid intake, increased exercise, hyperuricemia, and a history of kidney stones. Most stones pass spontaneously within 48 hours, but some may not.40
Factors influencing stone passage include:
Nephrolithiasis, a term for kidney stones, is a stone-forming process with an 80% chance of passage for a 4 mm stone and 20% for a 5 mm stone. If a stone doesn't pass, procedures may be required. The term originates from Greek words for "kidney" and "stone," and is related to renal calculus, a Latin term for stones.41
<a href="https://www.ijpsjournal.com/uploads/createUrl/createUrl-20250603121958-8.png" target="_blank">
<img alt="Kidney Stone.png" height="150" src="https://www.ijpsjournal.com/uploads/createUrl/createUrl-20250603121958-8.png" width="150">
</a>
Figure No. 3: Kidney Stone
Both men and women are susceptible to kidney stones, but young men are often at a higher risk than young women.42 Global warming's effects, primarily in the southeast of the USA, are predicted to increase the number of kidney stones in people's lifetimes from 1.6 million to 2.2 million by 2050.43
Generally, nephrolithiasis is more common in males as compared to females. Mainly six main types of stones are calcium oxalate-containing stone, calcium phosphate-containing stone, cystine-containing stone, uric acid stone, xanthine, and struvite-containing stone. The main causes of nephrolithiasis are hypercalciuria, hyperoxaluria, hypocitraturia, hyperuricosuria, hypomagnesuria, gouty diathesis, etc.
Inflammatory bowel diseases and gastric bypass surgery influence calcium ion absorption and increase calcium precipitation, leading to nephrolithiasis due to the formation of stone-forming substances.
Drug: Loop diuretics, antacids, acetazolamide, glucocorticoids, theophylline, vitamins D and C, and others have an incidental correlation with the occurrence of renal calculi.
Recurrence: Stone disease recurrence is a common clinical issue, with patients more likely to experience early recurrence due to urinary metabolic abnormalities like low urine volume, hypercalciuria, and hyperoxaluria. Major risk factors include male gender, multiple stones, stone placement, residual fragments, and urinary system abnormalities.
Occupation: The role of occupation in stone formation is a topic of debate. Geographic factors such as Stone Belt residence, lifestyle changes, unhealthy dietary habits, physical manual labor, low socioeconomic status, malnutrition, and reduced fluid intake contribute to kidney-related complications. Some experts suggest that this increased risk may be due to the release of vasopressin, a hormone that increases urine concentration during stress, and other factors.
Molecular Aspects: The role of occupation in stone formation is a topic of debate. Factors like Stone Belt residence, lifestyle changes, unhealthy diets, manual labor, low socioeconomic status, malnutrition, and reduced fluid intake contribute to kidney-related complications. Experts suggest increased risk may be due to vasopressin release during stress.44
Types of Kidney Stones
The chemical composition of kidney stones is determined by urine-based anomalies, which affect their size, form, and chemical content. Kidney stones are classified into five categories based on changes in mineral composition.45
<a href="https://www.ijpsjournal.com/uploads/createUrl/createUrl-20250603121958-7.png" target="_blank">
<img alt="4.png" height="150" src="https://www.ijpsjournal.com/uploads/createUrl/createUrl-20250603121958-7.png" width="150">
</a>
<a href="https://www.ijpsjournal.com/uploads/createUrl/createUrl-20250603121958-6.png" target="_blank">
<img alt="Types of Kidneys Stone.png" height="150" src="https://www.ijpsjournal.com/uploads/createUrl/createUrl-20250603121958-6.png" width="150">
</a>
Figure No. 4: Types of Kidneys Stone
There are four primary types of urinary calculi.
I) Calcium Stones
Calcium stones, which make up about 80% of urinary calculi, are the predominant type of kidney stones. They are primarily composed of calcium oxalate (CaOx) (50% pure), calcium phosphate (5%), and a mixture of both (45%). The main constituent of calcium stones is brushite (calcium hydrogen phosphate) or hydroxyapatite. Calcium oxalate is found in the majority of kidney stones and can be found in the form of CaOx monohydrate (COM), CaOxdihydrate (COD), or a combination of both. Factors contributing to CaOx stone formation include hypercalciuria, hyperuricosuria, hyperoxaluria, hypocitraturia, hypomagnesuria, and hypercystinuria. Urinary pH of 5.0 to 6.5 promotes CaOx stones, while calcium phosphate stones occur when pH is greater than 7.5. Kidney stone disease affects 12% of the global population and is associated with major health concerns such as coronary artery disease and chronic kidney disease. Despite being one of the oldest known and most common diseases worldwide, our understanding of the mechanisms underlying stone formation is lacking. Recent advancements have shed light on the nuanced contribution of diet, environment, genetics, calcium oxalate crystallization, Randall's plaque formation, inflammation, and the recently discovered urinary microbiome. In conclusion, the understanding of kidney stone pathogenesis is limited, and new therapeutic options for preventing and managing this disease will require an improved understanding of the causes of kidney stones.46
II) Struvite or Magnesium Ammonium Phosphate Stones
Struvite stones, also known as infection stones or triple phosphate stones, are 10-15% in size and are often caused by chronic urinary tract infections, causing urease production. Urease is needed to convert urea into ammonia and CO2, making urine more alkaline and increasing pH. Phosphate precipitates on insoluble ammonium products, leading to a large staghorn stone formation. Women are more likely to develop this type of stone than men. Struvite stones often form large staghorn calculi, which can obstruct renal function and lead to recurrent infections if not managed properly. Congenital and acquired anatomical abnormalities also contribute to stone formation by impairing urinary drainage and promoting urinary stasis. Medullary sponge kidney, horseshoe kidney, and ureteropelvic junction obstruction are some of the conditions that predispose individuals to recurrent calcium-based stones. Management of such cases requires a combination of medical and surgical interventions.47
III) Uric Acid Stones or Urate
Uric acid (UA) stones account for 3-10% of all kidney stones, with diets high in purines, particularly animal protein diets, causing hyperuricosuria, low urine volume, and low urinary pH. Nephrolithiasis is the most common cause, and uric acid stones are more common in men. The prevalence of UA stones increases regularly due to their high correlation with obesity, hypertension, metabolic syndrome, type 2 diabetes, and aging. UA stone formation is mainly due to an acidic urinary pH secondary to impaired urinary ammonium availability. Alkalization of urine is advocated to prevent UA crystallization and is considered an effective therapy. Urology treats urolithiasis, which is prevalent in 5-13% of European countries, 10% in France, and 13% in the U.S. Calcium oxalate is the most frequent component of kidney stones, but UA stones are becoming more frequent, accounting for about 10% of all stones. Factors promoting UA crystallization include an overly acidic urinary pH, hyperuricosuria, and insufficient diuresis. Obesity is the main factor for UA stone formation, responsible for metabolic syndrome and insulin resistance, resulting in decreased ammonia availability and low urine pH.48
IV) Cystine Stones
Cystine stones are a rare and often recurrent condition in the urinary tract, accounting for up to 10% of pediatric stone diseases. The two genes responsible for cystinuria are SLC3A1 and SLC7A9. These genes encode the heavy subunit rBAT of a renal b(0,+) transporter, while SLC7A9 encodes its interacting light subunit b(0,+)AT. Mutations in these genes are generally associated with an autosomal recessive mode of inheritance, while SLC7A9 variants result in broad clinical variability even within the same family. Cystine stones are yellowish with a waxy appearance macroscopically and characterized by a flat hexagonal crystal microscopically. They can be distinguished from smooth stones using helical CT in vitro, suggesting that it may be possible to distinguish these stones preoperatively. Cystinuria is a rare cause of urolithiasis, with affected patients having an earlier onset and more aggressive disease than those with other stone types. Current treatment options for cystinuria are limited in their effectiveness at preventing stone recurrence and are often poorly tolerated. Multiple studies suggest that L-CDME is as effective at inhibiting the growth of cystine crystals in vitro as well as in vivo. Additionally, the nutritional supplement α-LA prevents the formation of cystine stones, making it a potentially promising therapy for cystine stones. Clinical trials to support the use of these modalities are warranted.49
V) Drug-Induced Stones
Kidney stone disease is a long-term, recurrent condition affecting mature and aging men, involving the formation of urinary stones in the kidneys and urinary tract. A rare form, drug-induced urinary stones, accounts for about 1% of all stone types. CT scans predict successful fragmentation during ESWL, and it is a special ADR, classified as a subtype of crystal nephropathy. Diagnosing drug-induced kidney stone disease is difficult due to the possibility of recognizing the condition even after treatment cessation. There are two main types of drug-induced urinary stones: those composed of the drug and/or its metabolites, and those classified as "metabolic stones."50
Urinary stones are composed of crystals and noncrystalline phases, with the organic matrix consisting of macromolecules such as glycosaminoglycans (GAGs), lipids, carbohydrates, and proteins. The matrix acts as a template for kidney stone assembly, with phospholipids representing about 10.3% of the stone matrix. Brushite stone is a hard phosphate mineral with an increasing incidence rate, and a quarter of calcium phosphate (CaP) patients form stones containing brushite. In the urinary tract, CaP may be present in the form of hydroxyapatite, carbonate apatite, or brushite (calcium monohydrogen phosphate dihydrate, CaHPO4·2H2O). Brushite is resistant to shock waves and ultrasonic lithotripsy treatment. Nephrolithiasis is one of the most frequent urologic diseases. This study aimed to study the composition and frequency of 8854 patient kidney stones and their metabolic risk factors related to their type of calculi. Physicochemical and crystallographic methods were used to assess kidney stone composition. In a subset of 715 patients, 79% of stones were made of calcium salts (oxalate and phosphate), followed by uric acid stones in 16.5%, calcium salts and uric acid in 2%, other salts in 1.9%, and cystine in 0.6%. The male-to-female ratio was almost three times higher in calcium salts and other types of stones, reaching a marked male predominance in uric acid stones. The results show that analysis of kidney stone composition and corresponding metabolic diagnosis may provide a scientific basis for the best management and prevention of kidney stone formation and help study the mechanisms of urine stone formation. A study of 715 patients with kidney stones found that 66.7% had calcium-oxalate (CaOx) as the main composition, followed by uric acid (21%), calcium-phosphate (3%), calcium-phosphate + struvite (2.5%), struvite (2.2%), and calcium oxalate-uric acid (1.0%). Calcium oxalate kidney stones were mainly present in patients with idiopathic hypercalciuria, followed by unduly acidic urine pH and hyperuricosuria (68%). In uric acid stones, unduly acidic urine pH reached 70.6% of the total risk factor diagnosis. Multiple risk factors were observed in 14.7% of calcium-oxalate, 25.0% of struvite, 25.0% of oxalate-calcium phosphate, 11.6% of uric acid stone, and 28.6% of calcium oxalate-uric acid kidney stones. LUV was present in some calcium oxalate stones, uric stones, and calcium phosphate stones. An accurate analysis of kidney stone composition may provide a scientific basis for the best management and prevention of kidney stone formation and help study the mechanisms of kidney stone formation. Physical methods such as X-ray diffraction (XRD) and Fourier transform infrared spectroscopy (FTIR) are currently used for stone analysis. In a series of 8854 consecutive patients, 79.0% were made of calcium salts (oxalate and phosphate), followed by uric acid stones in 16.5%, calcium salts and uric acid in 2.0%, other salts in 1.9%, and cystine in 0.6%.51
|
Types of Stones |
Incidence |
|
Pure Calcium Oxalate |
33% |
|
Mixed Calcium Oxalate and Phosphate |
34% |
|
Struvite |
15% |
|
Uric Acid |
8% |
|
Pure Calcium Phosphate |
6% |
|
Cystine |
3% |
|
Artifacts And Other |
1% |
D) Mechanism of kidney stone formation
Stone-forming crystalloids or substances in urine precipitate out of solution to develop an order for renal stones. The majority of stones, roughly 75% of them, are calcium-based and made of calcium oxalate, calcium phosphate, or a combination of oxalate and phosphate. These mixed stones have multiple components, such as calcium and uric acid accumulation. In susceptible patients, stone formation starts when urine is oversaturated with calcium, cystine, uric acid, struvite, or oxalate. Another 10% of kidney stones are uric acid-based, 1% are cystine-based, and the remainder are mostly struvite-based. Calcium oxalate (CaOx) and calcium phosphate (CaP) accumulate in various stages during the production of calcium stones. The creation of stones is being aided by this process. The process of forming a stone involves the nucleation of the crystals that make up the stone, their growth or aggregation to a size that can interact with an intrarenal structure, their retention within the kidney or renal collecting system, and then additional aggregation and secondary nucleation to form the clinical stone.
I) Urinary Supersaturation and Crystallization
Crystal growth in the kidneys is caused by urinary supersaturation, where crystalline particles form. Stone formers excrete millions of urine crystals daily, indicating supersaturation. The 5-10 minute transit time across the kidney makes it insufficient for crystals to form and grow large enough to be caught. Calcium oxalate crystals, which can only grow to a few microns at 1-2 mm/min, are excreted with urine and do not form stones. Urinary components like citrate and magnesium can impact solution supersaturation by reducing free ions by creating soluble complexes with calcium and oxalate.
<a href="https://www.ijpsjournal.com/uploads/createUrl/createUrl-20250603121958-5.png" target="_blank">
<img alt="formation of stone.png" height="150" src="https://www.ijpsjournal.com/uploads/createUrl/createUrl-20250603121958-5.png" width="150">
</a>
Figure No.5: formation of stone
II) Crystal Nucleation
Nucleation is the initial phase of a supersaturated solution transitioning from the liquid to the solid phase. Stone salts coalesce into loose clusters, which grow as new parts are added. In vitro and in vivo studies show that renal tubular cell damage can facilitate the formation of calcium oxalate crystals by providing building blocks for their heterogeneous nucleation. Membrane vesicles formed during cell decomposition after injury serve as calcium crystal nucleators. In vivo crystals found in renal tubules of hyperoxaluric rats are linked to cellular breakdown products.
III) Crystal Growth
Crystal growth is a process where fresh crystal components are added to a crystal nucleus to reduce total free energy. This process is crucial for particle and stone creation, and crystal development and aggregation play essential roles in every stage of stone development. The crystal surface binding substance in calcium oxalate crystals, formed from human urine, contains human serum albumin, glycoprotein, microglobulin, retinol-binding protein, transferrin, and prothrombin. It is a potent inhibitor of calcium oxalate crystal growth. The rate of crystal growth is low, and the transit time of tubular fluid through the kidney is only several minutes. The probability of a single particle achieving a pathophysiological relevant size through crystal growth alone is extremely low.
IV) Crystal Aggregation
Aggregation is the process by which a small, hard crystal in solution clings together to form a solid, likely causing clinga retention within the kidneys, according to all models of CaOs-Lithiasis, and is considered the most crucial stage in stone production.
1.8 Causes of Lithiasis
A. Dietary Factors
B. Metabolic Factors
C. Medical Conditions
D. Anatomical Factors
E. Medications and Supplements
F. Family History
G. Geographical and Climate Factors
Table No:2 Animal Models for Lithiasis 54,55,56
|
Type of approach |
Lithogenic agent |
Diet/administration |
Effects |
|
Cross-breeding |
Inbreeding hypercalciuric |
Multiple-generation inbred Multiple diets/agents applied |
Hypercalciuria Hyperoxaluria CaOx crystals Cap crystals |
|
Exogenous induction |
Sodium oxalate Glycolic acid Ethylene Glycol (EG) Hydroxy-L-proline (HLP) |
Intraperitoneal injection of 10 mg/kg sodium oxalate Free drinking of water with powdered 3% glycolic acid 0.75% EG in water with/without ammonium chloride, vitamin D, calcium chloride Intraperitoneal injection of 2.5 g/kg HLP Mixed in the chow of 5% HLP |
Prompt CaOx crystal deposits Crystal aggregation in the ducts of Bellini Hyperoxaluria Hypocitraturia CaOx crystal deposits Hyperoxaluria CaOx crystalluria CaOx crystal deposits Renal toxicity Hyperoxaluria CaOx crystal deposits are less toxic compared to other agents |
|
Dietary manipulation |
Potassium oxalate supplement Magnesium (Mg) deficiency Vitamin B6 (pyridoxine) deficiency |
% Level of potassium oxalate Dietary Mg deprivation Dietary intentional deficiency of pyridoxine |
CaOx crystal deposits Increase in CaP crystal deposits Hyperoxaluria Hypocitraturia CaOx crystal deposits |
|
Surgery |
Intestinal Resection Gastric Bypass Surgery |
Resection of the distal 40-45 cm of the terminal ileum Combination diet of high oxalate/low calcium/high lipid fat Roux-en-Y gastric bypass 40% fat and 1.5% sodium oxalate diet |
Hyperoxaluria Hypocitraturia CaOx, CaP, CaCO3 crystal deposits Hyperoxaluria CaOx crystal deposits |
1.9 Clinical Symptoms of Lithiasis
1.10 Symptoms of Lithiasis
1.11 Risk factors for kidney stones
In most cases, a definite cause is not found. Kidney stone risk is increased by a risk factors for kidney stones.
Kidney stone development in postmenopausal women is linked to hypertension and a magnesium and calcium-deficient diet. Patients with binary tract anatomical shape calcium are more likely to develop stones. About 25 cure stones are idiopathic in origin, and up to 80% of individuals with calcium stones have metabolic risk factors. Many medications also increase the risk of stone disease.58,59
1.12 Anatomical abnormalities that increase the risk of stone disease
1.19 Treatment of kidney stones
Urine Alkalization
Currently, there are four methods of stone removal
Failure rate: 30%-89% after initial session. Identification of suitable candidates can reduce the failure rate.63
<a href="https://www.ijpsjournal.com/uploads/createUrl/createUrl-20250603121958-4.png" target="_blank">
<img alt="Extracorporeal Shockwave Lithotripsy.png" height="150" src="https://www.ijpsjournal.com/uploads/createUrl/createUrl-20250603121958-4.png" width="150">
</a>
Figure No.6: Extracorporeal Shockwave Lithotripsy
Percutaneous nephrolithotomy (PCNL) is a procedure used to remove kidney stones from the urinary tract using a nephroscope passed into the kidney through a track created in the patient's back. It was first performed in Sweden in 1973 as a less invasive alternative to open surgery on the kidneys.
<a href="https://www.ijpsjournal.com/uploads/createUrl/createUrl-20250603121958-3.png" target="_blank">
<img alt="Percutaneous Nephrolithotomy.png" height="150" src="https://www.ijpsjournal.com/uploads/createUrl/createUrl-20250603121958-3.png" width="150">
</a>
Figure No.7: Percutaneous Nephrolithotomy
Ureteroscopic Stone Removal and Acute Renal Failure
<a href="https://www.ijpsjournal.com/uploads/createUrl/createUrl-20250603121958-2.png" target="_blank">
<img alt="Ureteroscopic Stone Removal.png" height="150" src="https://www.ijpsjournal.com/uploads/createUrl/createUrl-20250603121958-2.png" width="150">
</a>
Figure No. 8: Ureteroscopic Stone Removal
<a href="https://www.ijpsjournal.com/uploads/createUrl/createUrl-20250603121958-1.png" target="_blank">
<img alt="Open (Incisional) and laparoscopic treatment.png" height="150" src="https://www.ijpsjournal.com/uploads/createUrl/createUrl-20250603121958-1.png" width="150">
</a>
Figure No. 9: Open (Incisional) and laparoscopic treatment
|
Sr. No. |
Herbal drugs |
Uses |
|
|
Melia Azedarach Linn.67
|
Traditionally, it is used as an anthelmintic, antilithic diuretic, emmenagogue, astringent, and stomachic. |
|
|
Petroselinum Sativum68
|
Diuretic Properties, Antioxidant Activity, Anti-inflammatory Effects, Alteration of Urine Composition |
|
|
Hygrophila Spinosa68
|
Jaundice and Liver Disorders, Rheumatism and Joint Pain, Renal Stones, Gonorrhea |
|
|
Relith68
|
Antiurolithiatic Activity |
|
|
Cucumis Trigonus68
|
Litholytic Activity, Anti-inflammatory and Antioxidant Properties |
|
|
Aerva Lanata And Vediuppu Chunam68
|
Antiurolithiatic, Diuretic, Antimicrobial, Anti-inflammatory, Antidiabetic, Hyperoxaluria Treatment |
In Ayurveda, several medicinal plants and Ayurveda compound formulations have been prescribed by Ayurveda doctors for the treatment of lithiasis.
Plant Profile69,70
<a href="https://www.ijpsjournal.com/uploads/createUrl/createUrl-20250603121958-0.jpg" target="_blank">
<img alt="Breynia rhamnoide mull-Arg.jpg" height="150" src="https://www.ijpsjournal.com/uploads/createUrl/createUrl-20250603121958-0.jpg" width="150">
</a>
Figure No. 11: Breynia rhamnoide mull-Arg
Name: Breynia rhamnoide mull-Arg
Famlily: Phyllanthaceae/ Euphorbiaceae
Vernacular Names: Hindi: Tikhar
Marathi: Mothi Kangali
Sanskrit: Aruni
Other Names : B. Vitis-Idaea, Commonly Known as Coral Berry Tree, Indian Snowberry, Mountain Coffee Bush, Civappu-P-Pula in Tamil, Arauni in Assamese, Bhita Shalapati in Bengali.
Taxonomical Classification
Table No. 2: Taxonomical Classification
|
Kingdom |
Plantae |
|
Subkingdom |
Tracheobionta |
|
Super division |
Spermatophyta (Seed plants) |
|
Division |
Magnoliophyta (Angiosperms - Flowering plants) |
|
Class |
Magnoliopsida (Dicotyledons) |
|
Subclass |
Rosidae |
|
Order |
Malpighiales |
|
Family |
Phyllanthaceae |
|
Genus |
Breynia |
|
Species |
Breynia rhamnoide |
Habitat: Andaman Is., Bangladesh, Cambodia, China South-Central, China Southeast, India, Malaya, Myanmar, Nicobar Is., Pakistan, Philippines, Sri Lanka, Sumatra, Thailand, Vietnam.
Medicinal Parts: The medicinal part is the dried herb.
Flowers and Fruits:
Leaves, Stem, and Roots:
The plant is a shrub or small tree, growing up to 2–4 meters in height.
Characteristics:
Chemical Constituents
The plant contains Preliminary phytochemical screening of B. Vitis-idea contains a variety of phytoconstituents such as alkaloids, flavonoids, carbohydrates, tannin, saponin, terpenoids, phenol, protein, steroids, and glycosides.71
Traditional medicinal uses
The Preliminary Phytochemical screening was performed the results are as follows:
Table No. 9: Phytochemical screening of Breynia rhamnoides extract
|
Sr. No |
Phytoconstituents |
Ethanol extract |
Aqueous extract |
|
1 |
Alkaloids |
+ve |
+ve |
|
2 |
Glycoside |
+ ve |
+ ve |
|
3 |
Flavonoids |
+ ve |
+ ve |
|
4 |
Tannins |
+ve |
+ve |
|
5 |
Terpenoids |
+ve |
+ve |
|
6 |
Saponins |
+ve |
+ve |
|
7 |
Phenols |
+ve |
+ve |
|
8 |
phenolic glycosides |
+ve |
+ve |
|
9 |
Carbohydrates |
-ve |
-ve |
|
10 |
Iridoids |
+ve |
+ve |
+ve indicates present -ve indicates absent
Preliminary Phytochemical Screening of ethanolic extract of Breynia rhamnoides shows the presence of Glycosides, Flavonoids, Tannins, Iridoids, Terpenoids, and Saponins.
In a study using high fructose diet-induced diabetic C57BL/6J ob/ob mice, Breynia rhamnoides leaf extracts demonstrated:
Extracts from Breynia species, including Breynia rhamnoides, have shown significant dose-dependent radical scavenging activity. The antioxidant properties are attributed to their phenolic and flavonoid contents. The plant exhibits significant antioxidant properties, primarily due to the presence of flavonoids, polyphenols, and other phenolic compounds. These compounds scavenge free radicals and reduce oxidative stress, which is implicated in aging and various chronic diseases. Methanolic and ethanolic extracts have shown potent DPPH and ABTS radical scavenging activity in in vitro assays.
Leaf extracts of Breynia vitis-idaea, a species closely related to Breynia rhamnoides, exhibited larvicidal properties against mosquito vectors such as Aedes aegypti, Culex quinquefasciatus, and Anopheles stephensi. This suggests potential for natural mosquito control agents.
Traditional applications in India include:
Wound Healing: Bark used for treating wounds.
Anti-inflammatory: Powdered dried bark and leaves used as smoke to treat swelling of the tongue and amygdala.
Postpartum Care: Leaf juice is given to mothers after childbirth.
Treatment of Skin Conditions: Leaves used for psoriasis and scabies.
Breynia rhamnoides has demonstrated anti-inflammatory effects in both acute and chronic models. The extracts inhibit the production of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6, and also downregulate the expression of COX-2 and iNOS enzymes, which are key players in the inflammation cascade.
Breynia rhamnoides stem extract has been utilized in the green synthesis of gold and silver nanoparticles. These biogenic nanoparticles effectively catalyze the reduction of 4-nitrophenol to 4-aminophenol, highlighting their potential in environmental remediation and industrial applications.
Breynia rhamnoides has been employed in various traditional remedies:
Breynia rhamnoides is an emerging medicinal plant that holds immense promise as a source of pharmacologically active constituents. With a history rooted in traditional medicine and increasing validation from preliminary scientific studies, this plant has demonstrated diverse therapeutic potentials, including antioxidant, anti-inflammatory, antimicrobial, antidiabetic, hepatoprotective, and wound healing properties. The growing interest in plant-based medicines makes Breynia rhamnoides a relevant candidate for further research and development in the field of phytomedicine and drug discovery. Despite encouraging findings from in vitro and in vivo studies, the integration of Breynia rhamnoides into modern medical practice remains limited due to several scientific and regulatory gaps. First and foremost, the isolation and structural characterization of its bioactive compounds are yet to be fully explored. Although preliminary phytochemical screening has confirmed the presence of flavonoids, alkaloids, tannins, phenolic acids, and saponins, advanced techniques such as HPLC, GC-MS, NMR, and LC-MS/MS are necessary to identify, purify, and characterize specific molecules responsible for the observed pharmacological actions. Identifying lead compounds with reproducible efficacy will also enable targeted drug development and structure-activity relationship (SAR) studies. Furthermore, standardization of plant extracts is essential for ensuring reproducibility, efficacy, and safety in both research and clinical settings. Variability in phytochemical content due to differences in geographical location, harvest time, and extraction methods poses a significant challenge. Standardized formulations will provide consistency in bioactive compound concentrations, which is vital for both experimental studies and therapeutic applications. A major bottleneck in the clinical advancement of Breynia rhamnoides is the lack of pharmacokinetic and pharmacodynamic data. These studies are critical to understanding the absorption, distribution, metabolism, and excretion (ADME) of its active components, as well as their interactions with cellular targets and signaling pathways. Understanding these mechanisms will help clarify the therapeutic window, dosing regimen, and potential drug-herb interactions.Moreover, comprehensive clinical trials are required to validate the safety and efficacy of Breynia rhamnoides in human subjects. Although traditional usage and animal models provide foundational insight, clinical evidence is indispensable for its approval and use in evidence-based medicine. Toxicological profiling, including genotoxicity, reproductive toxicity, and chronic toxicity, should also be prioritized to ensure long-term safety. Given its diverse pharmacological spectrum, Breynia rhamnoides has the potential to contribute meaningfully to natural drug discovery and integrative medicine. Its bioactive molecules could serve as leads for the development of new therapeutic agents, either as standalone drugs or as synergistic components in polyherbal formulations. In an era where antimicrobial resistance, chronic inflammation, and metabolic disorders are on the rise, natural compounds from plants like Breynia rhamnoides offer a promising complementary approach to conventional therapies. In conclusion, Breynia rhamnoides stands at the intersection of traditional wisdom and modern science. With targeted research focusing on its phytochemistry, pharmacology, and clinical validation, this underutilized plant could soon emerge as a valuable asset in the global pharmacopeia.
REFERENCES
Vaishnavi Shende*, Shailesh Shende, Kalyani Kathole, Dr. R. O. Ganjiwale, Dr. Bhushan Gandhare, Evaluation of Antilithiatic Activity of Bark Extracts of Breynia Rhamnoide Mull-Arg in Experimental Animals: A Review, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 6, 368-397. https://doi.org/10.5281/zenodo.15582006
10.5281/zenodo.15582006